Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Should You Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $42.11, but opened at $46.95. Zealand Pharma A/S shares last traded at $46.95, with a volume of 100 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ZLDPF shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

The business’s fifty day moving average is $47.30 and its two-hundred day moving average is $54.74. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $3.36 billion, a PE ratio of 3.48 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. The company had revenue of $5.33 million for the quarter, compared to the consensus estimate of $2.81 million. As a group, research analysts anticipate that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.